Works matching IS 01676997 AND DT 2016 AND VI 34 AND IP 1

Results: 15

Phase I, dose-escalating study of elisidepsin (Irvalec), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 75, doi. 10.1007/s10637-015-0305-8

By:

Goel, Sanjay;
Viteri, Santiago;
Morán, Teresa;
Coronado, Cinthya;
Dios, Jorge;
Miguel-Lillo, Bernardo;
Fernández-García, Eva;
Rosell, Rafael

Publication type:

Article

Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 1, doi. 10.1007/s10637-015-0301-z

By:

Yoon, Jin;
Hwang, Deok;
Kim, Eun;
Kim, Jung;
Kim, Sujong;
Chung, Hwa;
Lee, Sang;
Yi, Jun;
Uhm, Jieun;
Won, Young;
Park, Byeong;
Choi, Jung;
Lee, Young

Publication type:

Article

7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 15, doi. 10.1007/s10637-015-0302-y

By:

Russell, Eileen;
Guo, Jianfeng;
O'Sullivan, Elaine;
O'Driscoll, Caitriona;
McCarthy, Florence;
Cotter, Thomas

Publication type:

Article

Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 24, doi. 10.1007/s10637-015-0303-x

By:

Serrill, Jeffrey;
Wan, Xuemei;
Hau, Andrew;
Jang, Hyo;
Coleman, Daniel;
Indra, Arup;
Alani, Adam;
McPhail, Kerry;
Ishmael, Jane

Publication type:

Article

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 41, doi. 10.1007/s10637-015-0304-9

By:

Imbs, Diane-Charlotte;
Paludetto, Marie-Noelle;
Négrier, Sylvie;
Powell, Helen;
Lafont, Thierry;
White-Koning, Melanie;
Chatelut, Etienne;
Thomas, Fabienne

Publication type:

Article

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 84, doi. 10.1007/s10637-015-0306-7

By:

Amin, Manik;
Minton, Susan;
LoRusso, Patricia;
Krishnamurthi, Smitha;
Pickett, Cheryl;
Lunceford, Jared;
Hille, Darcy;
Mauro, David;
Stein, Mark;
Wang-Gillam, Andrea;
Trull, Lauren;
Lockhart, A.

Publication type:

Article

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 112, doi. 10.1007/s10637-015-0307-6

By:

Thakur, Manish;
Heilbrun, Lance;
Sheng, Shijie;
Stein, Mark;
Liu, Glenn;
Antonarakis, Emmanuel;
Vaishampayan, Ulka;
Dzinic, Sijana;
Li, Xiaohua;
Freeman, Stacy;
Smith, Daryn;
Heath, Elisabeth

Publication type:

Article

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 96, doi. 10.1007/s10637-015-0308-5

By:

Hubbard, Joleen;
Kim, George;
Borad, Mitesh;
Johnson, Elizabeth;
Qin, Rui;
Lensing, Janet;
Puttabasavaiah, Suneetha;
Wright, John;
Erlichman, Charles;
Grothey, Axel

Publication type:

Article

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 119, doi. 10.1007/s10637-015-0309-4

By:

Meulendijks, Didier;
Beerepoot, Laurens;
Boot, Henk;
Groot, Jan;
Los, Maartje;
Boers, James;
Vanhoutvin, Steven;
Polee, Marco;
Beeker, Aart;
Portielje, Johanna;
Jong, Robert;
Goey, Swan;
Kuiper, Maria;
Sikorska, Karolina;
Beijnen, Jos;
Tesselaar, Margot;
Schellens, Jan;
Cats, Annemieke

Publication type:

Article

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 49, doi. 10.1007/s10637-015-0310-y

By:

Barnard, Darlene;
Diaz, H.;
Burke, Teresa;
Donoho, Gregory;
Beckmann, Richard;
Jones, Bonita;
Barda, David;
King, Constance;
Marshall, Mark

Publication type:

Article

Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 61, doi. 10.1007/s10637-015-0311-x

By:

Shah, Nirali;
Cole, Diane;
Lester-McCully, Cynthia;
Wayne, Alan;
Warren, Katherine;
Widemann, Brigitte

Publication type:

Article

Acknowledgement of Reviewers 2015.

Published in:: Investigational New Drugs, 2016, v. 34, n. 1, p. 138, doi. 10.1007/s10637-015-0312-9
Publication type:: Article

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 104, doi. 10.1007/s10637-015-0313-8

By:

Chiu, Joanne;
Hotte, Sebastien;
Kollmannsberger, Christian;
Renouf, Daniel;
Cescon, David;
Hedley, David;
Chow, Sue;
Moscow, Jeffrey;
Chen, Zhuo;
Perry, Meghan;
Diaz-Padilla, Ivan;
Tan, David;
Hirte, Hal;
McWhirter, Elaine;
Chen, Helen;
Siu, Lillian;
Bedard, Philippe

Publication type:

Article

Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 129, doi. 10.1007/s10637-015-0315-6

By:

Yeh, Lee-Chuan;
Banerjee, Asok;
Prasad, Veena;
Tuszynski, Jack;
Weis, Alexander;
Bakos, Tamas;
Yeh, I-Tien;
Ludueña, Richard;
Lee, John

Publication type:

Article

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2016, v. 34, n. 1, p. 66, doi. 10.1007/s10637-015-0300-0

By:

Nokihara, Hiroshi;
Yamada, Yasuhide;
Fujiwara, Yutaka;
Yamamoto, Noboru;
Wakui, Hiroshi;
Nakamichi, Shinji;
Kitazono, Satoru;
Inoue, Kohei;
Harada, Akiko;
Taube, Tillmann;
Takeuchi, Yoshito;
Tamura, Tomohide

Publication type:

Article